• Notes: To generate a TNFR2 stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve), for antibiotic selection of transduced cells. Visit bpsbioscience.com/cell-line-faq for guidelines on how to perform a kill curve. Biosafety: The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email support@bpsbioscience.com.
• Shiptemp: -80°C (dry ice)
• Synonyms: NFRSF1B, TNFBR,Tumor necrosis factor receptor superfamily member 1B, Tumor necrosis factor receptor 2, TNF-R2, Tumor necrosis factor receptor type II, TNF-RII, TNFR-II, TNF-alpha receptor, CD120b
• Warnings: Avoid freeze/thaw cycles
• Category: CAR T-Cell /Lentivirus
• Background: Tumor Necrosis Factor Receptor 2 (TNFR2, also known as TNR1B, TNFRSF1B, or CD120b) is a transmembrane receptor of the TNF protein superfamily that binds the pleiotropic pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). TNFR2 can be found in several T-Cell subsets such as regulatory CD8+ T-Cells (Tregs) and CD4+ tumor infiltrating T cells, myeloid lineage cells and some cancer types, and it is involved in autoimmune diseases, graft versus host disease and cancer. It has become an attractive target for cancer immunotherapy, where its different functions as oncogene and immune regulator are being explored. TNFR2 also exhibits neuroprotective properties and promotes tissue regeneration, making it a promising potential therapeutic target for the treatment of Alzheimer 's disease.
• Description: The TNFR2 (Tumor Necrosis Factor Receptor 2, or TNR1B) Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with Human TNFR2 (NM_001066.3) driven by a CMV promoter. The lentiviruses also transduce a puromycin selection gene.
• Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
• Supplied As: Two vials (500 µl x 2) of lentivirus at a titer≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Applications: • Expression of human TNFR2 in cells of interest. • Generate stable cell lines expressing human TNFR2 (puromycin resistant).
• Product Type: Lentivirus
• Biosafety Level: BSL-2
• Related Products: 79363, 100205, 79750
• Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. 
• Scientific Category: CAR T-Cell Therapy, Immunotherapy

DESCRIPTION